Published Date : Apr 25, 2016
ALBANY, New York, April 25, 2016 - MarketResearchReports.biz has announced the addition of the “PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast And Market Analysis To 2024” report to its offering. The detailed report contains data about the current state of the global hepatitis B virus (HBV) therapeutics market. It studies the market’s opportunities and the potential challenges faced by the hepatitis B virus therapeutics market. The impact of drivers and challenges is also studied. The report helps readers discover trends in the hepatitis B virus therapeutics market and identify the strategic consolidations shaping the industry. According to the report, the hepatitis B virus therapeutics market in the 8MM will be worth about US3.0 bn in 2024; it was valued at US$2.4 bn in 2014 and will expand at a mediocre CAGR of 2.4% from 2014 to 2024.
The report contains an overview of chronic HBV infection, including diagnosis, etiology, current treatment options, pathophysiology, epidemiology, and symptoms. It assesses the HBV therapeutics market’s revenue in the period from 2014 to 2024. The annual cost of therapy and major pipeline product sales are also analyzed.
Hepatitis B is a serious liver disease and occurs as a result of transmission of the virus through the blood or other bodily fluids of an infected person. Although effective prophylactic vaccines are available to combat the disease, hepatitis B remains a concern for people across the globe, as 350 mn people are living with this condition. People suffering from chronic hepatitis B have a high risk of suffering from other life-threatening disorders or complications such as liver cancer, hepatocellular carcinoma, and liver cirrhosis. Moreover, around 786,000 hepatitis B-related deaths have occurred in 2010. Thus, the global hepatitis B virus therapeutics market is growing to combat the growing spread of the disease.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/699493
The available treatment for chronic hepatitis B includes oral nucleoside/nucleotide analogues (NAs), viral suppression, and pegylated interferon (PEG-IFN). Out of these therapies, the NA therapy is majorly used by patients as a long-term treatment, owing to its low cost.
The report studies the hepatitis B virus therapeutics market in the 8 major markets– Germany, the US, Italy, Spain, the UK, China, Japan, and France. The market in 8MM is expected to be driven by the rising adoption of therapies with novel mechanisms of action (MOAs). Pipeline agents have the potential to address some of the unmet needs in the hepatitis B treatment landscape, but clinical data will be necessary to prove their advantage over other available therapies. The report states that there will be many opportunities centered around the development of antivirals with novel MOAs, since they can improve the efficacy of the existing drugs for hepatitis B.
Major players in the hepatitis B virus market studied in the report include: Gilead, Arrowhead Research, Bristol-Myers Squibb, Novartis, GlobeImmune, Roche, Merck, and GSK.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org